Evidence map›Paper›PMID 32312421›Full record

ReviewAdvances in protein chemistry and structural biology2020

Targeting arrestin interactions with its partners for therapeutic purposes.

Vsevolod V Gurevich, Eugenia V Gurevich

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in protein chemistry and structural biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Vsevolod V GurevichDepartment of Pharmacology, Vanderbilt University, Nashville, TN, United States.
Eugenia V GurevichDepartment of Pharmacology, Vanderbilt University, Nashville, TN, United States.

Funding

STRUCTURE/FUNCTION STUDIES OF VISUAL ARRESTINR01EY011500 · NEI · VANDERBILT UNIVERSITY · PI T M Iverson · 1997 to 2026
$12.3M
Targeted Engineering of Designer Arrestins to Regulate Cell SignalingR35GM122491 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2017 to 2021
$2.6M
Arrestin interactions with non-receptor binding partnersR01GM077561 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2007 to 2015
$2.3M
Signaling regulation in the striatum in Parkinson's diseaseR01NS065868 · NINDS · VANDERBILT UNIVERSITY · PI GUREVICH, EUGENIA V · 2009 to 2013
$1.7M
Regulation of GPCR signaling with receptor-specific arrestinsR01GM109955 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2015 to 2017
$1.1M
The role of receptor desensitization machinery in psychostimulant addictionR21DA030103 · NIDA · VANDERBILT UNIVERSITY · PI GUREVICH, EUGENIA V · 2011 to 2012
$390k
NEI NIH HHS R01 EY011500NIDA NIH HHS R21 DA030103NIGMS NIH HHS R01 GM077561NIGMS NIH HHS R01 GM109955NIGMS NIH HHS R35 GM122491NINDS NIH HHS R01 NS065868
6 · The paper itself

Abstract

Most vertebrates express four arrestin subtypes: two visual ones in photoreceptor cells and two non-visuals expressed ubiquitously. The latter two interact with hundreds of G protein-coupled receptors, certain receptors of other types, and numerous non-receptor partners. Arrestins have no enzymatic activity and work by interacting with other proteins, often assembling multi-protein signaling complexes. Arrestin binding to every partner affects cell signaling, including pathways regulating cell survival, proliferation, and death. Thus, targeting individual arrestin interactions has therapeutic potential. This requires precise identification of protein-protein interaction sites of both participants and the choice of the side of each interaction which would be most advantageous to target. The interfaces involved in each interaction can be disrupted by small molecule therapeutics, as well as by carefully selected peptides of the other partner that do not participate in the interactions that should not be targeted.

Indexed as

AnimalsArrestinsBinding SitesGene Expression RegulationGenetic TherapyHumansLeber Congenital AmaurosisMolecular Targeted TherapyMutationProtein BindingReceptors, G-Protein-CoupledRetinal Rod Photoreceptor CellsSignal TransductionSmall Molecule LibrariesArrestinsReceptors, G-Protein-CoupledSmall Molecule LibrariesArrestinGene therapyGPCRProtein-protein interactionsReceptor specificitySignalingSignaling bias

Identifiers

PMID32312421
PMCPMC7977737

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.